Premium
Midpoint CD34 measurement as a predictor of PBPC product yield in pediatric patients undergoing high‐dose chemotherapy
Author(s) -
Sidhu Rameshwar S.,
Orsini Edmund,
Giller Roger,
Quis Ralph,
Foreman Nicholas K.,
Thompson Hannis,
Brimhall Brad,
Walton Karen,
Croskell Melissa,
Le Tuan N.
Publication year - 2006
Publication title -
journal of clinical apheresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.697
H-Index - 46
eISSN - 1098-1101
pISSN - 0733-2459
DOI - 10.1002/jca.20080
Subject(s) - medicine , chemotherapy , yield (engineering) , surgery , metallurgy , materials science
High‐dose chemo/radiotherapy of sensitive tumors requires PBPC rescue doses of >3×10 6 CD34/kg (range: 3–20×10 6 CD34/kg). Because of the diversity of stem cell treatment protocols and clinical presentation of patients at the time of peripheral blood progenitor cell (PBPC) harvest, the use of the mid‐point CD34 positive cell measurement was initiated to predict the final CD34‐positive cell product yield/stem cell harvest. The measurement of CD34‐positive cells at the mid‐point of the initial setting of 5 total blood volumes (TBV) allows for the extension, shortening, or no change in the TBV processing to achieve a maximum goal of CD34‐positive cells/kg body weight required for stem cell transplantation. The estimation of mid‐point CD34‐positive cells guided our center to extend 22 procedures, shorten 26 procedures, and leave 20 procedures unchanged. This investigation addresses three aspects of PBPC collection in pediatric patients: (1) the processing of large blood volumes (more than the defined 3 TBV and maximum up to 13 TBV in one session) to achieve good efficiency of the procedure; (2) the use of the mid‐point CD34 measurement at 2.5 of 5 TBV initially set to predict the maximum goal of CD34 cells /kg needed on the same day of PBPC collection; and (3) PBPC collection in pediatric patients <10 kg body weight (as low as 5.8 kg body weight). J. Clin. Apheresis 2006. © 2006 Wiley‐Liss, Inc.